Welcome to Journal Watch. The content you requested requires sign in with a username and password.
Lenalidomide for Myelodysplasia
About one quarter of low-risk MDS patients became transfusion independent after a median of 5 weeks of therapy.
Sign In
Don't yet have a username or password?
Register now for
Journal Watch e-mail alerts and unlimited online
access to articles 6 months after publication.
Subscribe now for
Full, immediate online access to all Journal Watch content and services.
Already a subscriber? Activate your subscription to receive full online access.
Get full site access with a 7-day site pass for $19